Cover Image
市場調查報告書

Neovacs SA :產品平台分析

Neovacs SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253786
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Neovacs SA :產品平台分析 Neovacs SA - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 29 Pages
簡介

Neovacs SA 是致力於開發自體免疫疾病和發炎性疾病治療的疫苗的生物科技企業。該公司提供臨床試驗中的產品,用於類風濕性關節炎、克隆氏症、癌症、紅斑性狼瘡等治療。

本報告提供Neovacs SA的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Neovacs SA的基本資料

  • Neovacs SA概要
  • 主要資訊
  • 企業資料

Neovacs SA:R&D概要

  • 主要的治療範圍

Neovacs SA:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Neovacs SA:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Neovacs SA:藥物簡介

  • 全身紅斑,慢性病毒感染及皮膚肌炎干擾素Alpha為目標的疫苗
  • 克隆氏症,慢性風濕病及乾癬 TNFAlpha標的疫苗
  • 過敏白細胞介素4及白細胞介素13標的疫苗
  • 老齡化性黃斑部病變及固體腫瘤VEGF-Alpha標的疫苗

Neovacs SA:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型

Neovacs SA:最近的開發平台趨勢

Neovacs SA:暫停中的計劃

Neovacs SA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07939CDB

Summary

Global Markets Direct's, 'Neovacs SA - Product Pipeline Review - 2015', provides an overview of the Neovacs SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neovacs SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Neovacs SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neovacs SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neovacs SA's pipeline products

Reasons to buy

  • Evaluate Neovacs SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neovacs SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neovacs SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neovacs SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neovacs SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neovacs SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Neovacs SA Snapshot
    • Neovacs SA Overview
    • Key Information
    • Key Facts
  • Neovacs SA - Research and Development Overview
    • Key Therapeutic Areas
  • Neovacs SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Neovacs SA - Pipeline Products Glance
    • Neovacs SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Neovacs SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Neovacs SA - Drug Profiles
    • Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target TNF Alpha for Crohn's Disease, Rheumatoid Arthritis and Psoriasis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target VEGF-Alpha for Age Related Macular Degeneration and Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neovacs SA - Pipeline Analysis
    • Neovacs SA - Pipeline Products by Target
    • Neovacs SA - Pipeline Products by Route of Administration
    • Neovacs SA - Pipeline Products by Molecule Type
  • Neovacs SA - Recent Pipeline Updates
  • Neovacs SA - Dormant Projects
  • Neovacs SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Neovacs SA, Key Information
  • Neovacs SA, Key Facts
  • Neovacs SA - Pipeline by Indication, 2015
  • Neovacs SA - Pipeline by Stage of Development, 2015
  • Neovacs SA - Monotherapy Products in Pipeline, 2015
  • Neovacs SA - Phase II, 2015
  • Neovacs SA - Preclinical, 2015
  • Neovacs SA - Pipeline by Target, 2015
  • Neovacs SA - Pipeline by Route of Administration, 2015
  • Neovacs SA - Pipeline by Molecule Type, 2015
  • Neovacs SA - Recent Pipeline Updates, 2015
  • Neovacs SA - Dormant Developmental Projects,2015
  • Neovacs SA, Subsidiaries

List of Figures

  • Neovacs SA - Pipeline by Top 10 Indication, 2015
  • Neovacs SA - Pipeline by Stage of Development, 2015
  • Neovacs SA - Monotherapy Products in Pipeline, 2015
  • Neovacs SA - Pipeline by Top 10 Target, 2015
  • Neovacs SA - Pipeline by Top 10 Route of Administration, 2015
  • Neovacs SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top